| Nov 14 |
Moleculin accelerates data readout for its late-stage leukemia treatment to H2 2025
|
| Nov 14 |
Moleculin Accelerates Planned Unblinded Data Readout for MIRACLE Phase 3 R/R Acute Myeloid Leukemia (AML) Pivotal Trial to H2 2025
|
| Nov 13 |
Moleculin Biotech Reports Financial Highlights and Future Plans
|
| Nov 12 |
Moleculin Receives Institutional Review Board Approval for MIRACLE Phase 3 Pivotal Trial of Annamycin in Combination with Cytarabine for the Treatment of R/R Acute Myeloid Leukemia (AML)
|
| Nov 12 |
Q3 2024 Moleculin Biotech Inc Earnings Call
|
| Nov 11 |
Moleculin Biotech, Inc. (MBRX) Q3 2024 Earnings Call Transcript
|
| Nov 11 |
Moleculin Biotech GAAP EPS of -$2.85
|
| Nov 11 |
Moleculin Reports Third Quarter 2024 Financial Results and Provides Corporate Update
|
| Nov 5 |
Moleculin to Report Third Quarter 2024 Financial Results on November 8, 2024 and Host Conference Call and Webcast
|
| Nov 4 |
Moleculin Appoints Leading Expert in Pancreatic Cancer to its Scientific Advisory Board to Support Development of Annamycin
|
